People
Geneviève Michaux is a Belgian- and French-qualified lawyer in the FDA and Life Sciences practice.
Recognized as one of the most highly regarded European Union (EU) life sciences regulatory specialists, Geneviève assists companies on a wide variety of issues under EU and national (French and Belgian) food and drug laws and regulations, with an emphasis on regulatory matters involving drugs, biologics, medical devices, cosmetics and food. She also advises life sciences clients on significant policy developments in the EU and assists with broader European and global projects.
Geneviève’s work spans matters ranging from regulatory status of borderline products, authorization procedures, life cycle management, clinical trials and investigations, labeling, advertising and promotions for all categories of products, and issues raised by specific categories of medicinal products, such as pediatric, orphan or advance therapy medicinal products. She has advised on various issues arising out of the EU Pediatric Regulation, EU Orphan Regulation, SPC and SPC extension, and ATMPs at the European and national level. She also counsels startups on establishing themselves in the EU as well as complying with advertising and scientific information rules, regulatory and legal guidance.
She assists life sciences companies in forming patient/compassionate use programs in Europe, negotiating and drafting consortia related agreements, reviewing clinical trial and clinical investigation agreements, interacting with healthcare professionals in connection with advertising and promotion efforts, and product classification matters such as borderlines between drug, medical device, cosmetic and food supplement, and assistance with local authorities.
Geneviève has extensive litigation experience in life science matters, including product liability and advertising and promotional activities.
Geneviève is recognized as one of the "Most Highly Regarded Individuals" in the regulatory field (Who's Who Legal, Life Sciences 2016). In the same publication, her clients reported that she has an "unsurpassed knowledge of legal areas," as well as being "extremely dedicated to the case and the client." She has published numerous articles on food and drug law and speaks at legal and regulatory conferences on pharmaceuticals and medical devices.
Publications
Speaking Engagements
Law Degree, Harvard Law School
Law Degree, Universite Libre de Bruxelles, Belgium, Magna Cum Laude
Brussels
Paris
Foreign Correspondent Member of the National Academy of Pharmacy (France)
Mediator with the Brussels Business Mediation Center
Member of the DIA Advisory Committee for Europe Middle East Africa
Member of the editorial board of SCRIP Regulatory Affairs
Dutch
English
French
December 7, 2021
King & Spalding Advises Oaktree Acquisition Corp. II in its Merger with Alvotech
August 14, 2024
European Union: Commission zeroes in on innovation in merger control and pay-for-delay cases
August 6, 2024
A Primer On EU's Updated Human Substance Regulations
December 7, 2021
King & Spalding Advises Oaktree Acquisition Corp. II in its Merger with Alvotech
August 14, 2024
European Union: Commission zeroes in on innovation in merger control and pay-for-delay cases
August 6, 2024
A Primer On EU's Updated Human Substance Regulations
December 7, 2021
King & Spalding Advises Oaktree Acquisition Corp. II in its Merger with Alvotech
Law Degree, Harvard Law School
Law Degree, Universite Libre de Bruxelles, Belgium, Magna Cum Laude
Brussels
Paris
Foreign Correspondent Member of the National Academy of Pharmacy (France)
Mediator with the Brussels Business Mediation Center
Member of the DIA Advisory Committee for Europe Middle East Africa
Member of the editorial board of SCRIP Regulatory Affairs
Dutch
English
French